Clinical significance of screening for subclinical Cushing’s disease in patients with pituitary tumors
-
- Tamada Daisuke
- Departments of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Kitamura Tetsuhiro
- Departments of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Otsuki Michio
- Departments of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Oshino Satoru
- Departments of Neurosurgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Saitoh Youichi
- Departments of Neurosurgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan Department of Neuromodulation and Neurosurgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
-
- Shimomura Iichiro
- Departments of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
書誌事項
- タイトル別名
-
- Clinical significance of screening for subclinical Cushing’s disease in patients with pituitary tumors
この論文をさがす
抄録
Cushing’s syndrome (CS) is a clinical state caused by chronic excess of glucocorticoid, and results in hypertension, impaired glucose tolerance, and dyslipidemia. Recently, a mild state of pituitary CS without typical Cushingoid appearance (subclinical Cushing’s disease; SCD) has been identified. However, the true prevalence of SCD and its effect on metabolic disorders remain obscure. The aim of this prospective study was to determine the prevalence of SCD according to the guideline proposed by the working group of the Japanese Ministry of Health, Welfare and Labor, and to assess the outcome of surgery on metabolic disorders. The prevalence of SCD was investigated in 105 consecutive patients diagnosed with pituitary adenomas by MRI. ACTH-dependent hypercortisolism was diagnosed based on the results of the 0.5 mg dexamethasone suppression test (serum cortisol >3.0 μg/dL) plus one positive finding of the following two tests: midnight serum cortisol level >5.0 μg/dL or ACTH increase >50% after 1-deamino-5-D-arginine vasopressin (DDAVP) challenge. The final diagnosis of SCD was established by positive staining for ACTH in surgically-excised pituitary adenoma. Three patients (4.8%) were diagnosed with SCD among 62 patients with pituitary adenoma. Transsphenoidal adenomectomy partially resulted in improvement of blood pressure and glucose metabolism in SCD patients. Our results emphasize the importance of SCD screening in patients with pituitary tumors, especially in those patients with metabolic disorders.
収録刊行物
-
- Endocrine Journal
-
Endocrine Journal 63 (1), 47-52, 2016
一般社団法人 日本内分泌学会